ArticleOncotarget2016

Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.

Binghe Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.